86 related articles for article (PubMed ID: 35921760)
1. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.
Borazanci E; Schram AM; Garralda E; Brana I; Vieito Villar M; Spreafico A; Oliva M; Lakhani NJ; Hoffman K; Hallett RM; Maetzel D; Hua F; Hilbert J; Giblin P; Anido J; Kelly A; Vickers PJ; Wasserman R; Seoane J; Siu LL; Hyman DM; Hoff DV; Tabernero J
ESMO Open; 2022 Aug; 7(4):100530. PubMed ID: 35921760
[TBL] [Abstract][Full Text] [Related]
2. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
[TBL] [Abstract][Full Text] [Related]
3. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
4. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Cole CB; Morelli MP; Fantini M; Miettinen M; Fetsch P; Peer C; Figg WD; Yin T; Houston N; McCoy A; Lipkowitz S; Zimmer A; Lee JM; Pavelova M; Villanueva EN; Trewhitt K; Solarz BB; Fergusson M; Mavroukakis SA; Zaki A; Tsang KY; Arlen PM; Annunziata CM
J Exp Clin Cancer Res; 2023 Mar; 42(1):76. PubMed ID: 36991390
[TBL] [Abstract][Full Text] [Related]
5. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract][Full Text] [Related]
6. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
7. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP; Alonso-Gordoa T; Banerjee S; Wang D; Naidoo J; Standifer NE; Palmer DC; Cheng LY; Kourtesis P; Ascierto ML; Das M; Diamond JR; Hellmann MD; Carneiro BA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309722
[TBL] [Abstract][Full Text] [Related]
9. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
[TBL] [Abstract][Full Text] [Related]
10. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Gong J; Cao J; Zhang Q; Xu N; Zhao Y; Xing B; Miao Z; Wu Y; Pan H; Gao Q; Li X; Liu B; Li W; Pei Z; Xia H; Qi Q; Dai H; Shi Q; Yang J; Li J; Shen L
Cancer Immunol Immunother; 2022 Aug; 71(8):1897-1908. PubMed ID: 34984540
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
Joerger M; Calvo E; Laubli H; Lopez J; Alonso G; Corral de la Fuente E; Hess D; König D; Sanchez Perez V; Bucher C; Jethwa S; Garralda E
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38243906
[TBL] [Abstract][Full Text] [Related]
12. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler AL; Smith DC; Phillips T; Curti BD; Goel S; Mehta AN; Kuzel TM; Markovic SN; Rixe O; Bajor DL; Gajewski TF; Gutierrez M; Lee HJ; Gopal AK; Caimi P; Heath EI; Thompson JA; Ansari S; Jacquemont C; Topletz-Erickson A; Zhou P; Schmitt MW; Grilley-Olson JE
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385724
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
[TBL] [Abstract][Full Text] [Related]
15. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Robbrecht D; Grob JJ; Bechter O; Simonelli M; Doger B; Borbath I; Butler MO; Cheng T; Romano PM; Pons-Tostivint E; Di Nicola M; Curigliano G; Ryu MH; Rodriguez-Vida A; Schadendorf D; Garralda E; Abbadessa G; Demers B; Amrate A; Wang H; Lee JS; Pomponio R; Wang R
Clin Transl Sci; 2024 Feb; 17(2):e13736. PubMed ID: 38362837
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study.
Deng T; Liu Z; Han Z; Zhou H; Liu R; Li Y; Li S; Xiu P; Wang S; Zhang Y; Ba Y
Ther Adv Med Oncol; 2023; 15():17588359231186025. PubMed ID: 37529157
[TBL] [Abstract][Full Text] [Related]
17. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Bendell J; LoRusso P; Overman M; Noonan AM; Kim DW; Strickler JH; Kim SW; Clarke S; George TJ; Grimison PS; Barve M; Amin M; Desai J; Wise-Draper T; Eck S; Jiang Y; Khan AA; Wu Y; Martin P; Cooper ZA; Elgeioushi N; Mueller N; Kumar R; Patel SP
Cancer Immunol Immunother; 2023 Jul; 72(7):2443-2458. PubMed ID: 37016126
[TBL] [Abstract][Full Text] [Related]
18. First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors.
Guo Y; Wang Z; Zhou H; Pan H; Han W; Deng Y; Li Q; Xue J; Ge X; Wang S; Wang J; Zhang Y; Zhao C; Zhu H; Wang Y; Shen H; Liu D; Li J
BMC Cancer; 2024 Apr; 24(1):444. PubMed ID: 38600507
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Greengard E; Williams R; Moriarity B; Liu X; Minard CG; Reid JM; Fisher T; Evans E; Pastore DR; Zauderer M; Voss S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2024 Jun; 71(6):e30938. PubMed ID: 38520670
[TBL] [Abstract][Full Text] [Related]
20. First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Mahalingam D; Harb W; Patnaik A; Bullock A; Watnick RS; Vincent MY; Chen JJ; Wang S; Pestana H; Chao J; Mahoney J; Cieslewicz M; Watnick J
Commun Med (Lond); 2024 Jan; 4(1):10. PubMed ID: 38218979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
